微生理系统：社区采用需要什么。
Microphysiological systems: What it takes for community adoption.
机构信息
390834National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Exp Biol Med (Maywood). 2021 Jun;246(12):1435-1446. doi: 10.1177/15353702211008872. Epub 2021 Apr 25.
Abstract
Microphysiological systems (MPS) are promising tools which could substantially improve the drug development process, particularly for underserved patient populations such as those with rare diseases, neural disorders, and diseases impacting pediatric populations. Currently, one of the major goals of the National Institutes of Health MPS program, led by the National Center for Advancing Translational Sciences (NCATS), is to demonstrate the utility of this emerging technology and help support the path to community adoption. However, community adoption of MPS technology has been hindered by a variety of factors including biological and technological challenges in device creation, issues with validation and standardization of MPS technology, and potential complications related to commercialization. In this brief Minireview, we offer an NCATS perspective on what current barriers exist to MPS adoption and provide an outlook on the future path to adoption of these tools.
摘要
微生理系统（MPS）是一种很有前途的工具，可以极大地改进药物开发过程，特别是对于那些服务不足的患者群体，如患有罕见疾病、神经紊乱和影响儿科人群的疾病的患者。目前，由国家转化医学中心（NCATS）领导的美国国立卫生研究院（NIH）MPS 计划的主要目标之一是展示这项新兴技术的实用性，并帮助支持其走向社区采用。然而，MPS 技术的社区采用受到多种因素的阻碍，包括设备创建中的生物学和技术挑战、MPS 技术验证和标准化方面的问题，以及与商业化相关的潜在并发症。在这篇简短的综述中，我们从 NCATS 的角度介绍了目前 MPS 采用所存在的障碍，并对这些工具的未来采用路径进行了展望。
相似文献
1
Microphysiological systems: What it takes for community adoption.微生理系统：社区采用需要什么。
Exp Biol Med (Maywood). 2021 Jun;246(12):1435-1446. doi: 10.1177/15353702211008872. Epub 2021 Apr 25.
2
Organs-on-chips: Progress, challenges, and future directions.芯片上的器官：进展、挑战及未来方向。
Exp Biol Med (Maywood). 2017 Oct;242(16):1573-1578. doi: 10.1177/1535370217700523. Epub 2017 Mar 26.
3
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development.微生理系统：药物开发中采用的利益相关者的挑战。
Cells Tissues Organs. 2022;211(3):269-281. doi: 10.1159/000517422. Epub 2021 Aug 11.
4
Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.将组织芯片和微生理系统融入医学、生物学、药理学和毒理学的整体框架之中。
Exp Biol Med (Maywood). 2017 Oct;242(16):1559-1572. doi: 10.1177/1535370217732765.
5
Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.更广泛采用肝脏及相互连接的微生理系统所面临的机遇与挑战。
Exp Biol Med (Maywood). 2017 Oct;242(16):1593-1604. doi: 10.1177/1535370217708976. Epub 2017 May 15.
6
Gastrointestinal microphysiological systems.胃肠道微生理系统
Exp Biol Med (Maywood). 2017 Oct;242(16):1633-1642. doi: 10.1177/1535370217710638. Epub 2017 May 23.
7
The Emergence of Microphysiological Systems (Organs-on-chips) as Paradigm-changing Tools for Toxicologic Pathology.微生理系统（器官芯片）作为毒理病理学中改变范式的工具的出现。
Toxicol Pathol. 2019 Jan;47(1):4-10. doi: 10.1177/0192623318809065. Epub 2018 Nov 8.
8
Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.微生理系统在药物早期开发中的应用：当前应用及未来影响的展望。
J Toxicol Sci. 2021;46(3):99-114. doi: 10.2131/jts.46.99.
9
Monitoring of Microphysiological Systems: Integrating Sensors and Real-Time Data Analysis toward Autonomous Decision-Making.微生理系统监测：传感器集成与实时数据分析，实现自主决策。
ACS Sens. 2019 Jun 28;4(6):1454-1464. doi: 10.1021/acssensors.8b01549. Epub 2019 Apr 19.
10
The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.制药行业中微生理系统的现状和应用：国际创新和质量微生理系统联盟附属调查及评论。
Drug Metab Dispos. 2024 Feb 14;52(3):198-209. doi: 10.1124/dmd.123.001510.
引用本文的文献
1
Validation of microphysiological systems for interpreting patient heterogeneity requires robust reproducibility analytics and experimental metadata.验证用于解释患者异质性的微生理系统需要强大的可重复性分析和实验元数据。
Cell Rep Methods. 2025 Apr 21;5(4):101028. doi: 10.1016/j.crmeth.2025.101028. Epub 2025 Apr 14.
2
Revolutionizing Biomedical Research: Unveiling the Power of Microphysiological Systems with Advanced Assays, Integrated Sensor Technologies, and Real-Time Monitoring.变革生物医学研究：通过先进检测方法、集成传感器技术和实时监测揭示微生理系统的力量。
ACS Omega. 2025 Mar 10;10(10):9869-9889. doi: 10.1021/acsomega.4c11227. eCollection 2025 Mar 18.
3
Comparative analysis of the physiological and transport functions of various sources of renal proximal tubule cells under static and fluidic conditions in PhysioMimix T12 platform.在PhysioMimix T12平台上，对静态和流体条件下各种来源的肾近端小管细胞的生理和转运功能进行比较分析。
Drug Metab Dispos. 2025 Jan;53(1):100001. doi: 10.1124/dmd.124.001488. Epub 2024 Nov 22.
4
Advanced tissue technologies of blood-brain barrier organoids as high throughput toxicity readouts in drug development.血脑屏障类器官的先进组织技术在药物开发中作为高通量毒性读数。
Heliyon. 2024 Dec 2;11(1):e40813. doi: 10.1016/j.heliyon.2024.e40813. eCollection 2025 Jan 15.
5
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.在用于代谢功能障碍相关脂肪性肝病精准治疗的人源化肝脏微生理系统中野生型和高危PNPLA3变体的比较
Front Cell Dev Biol. 2024 Sep 11;12:1423936. doi: 10.3389/fcell.2024.1423936. eCollection 2024.
6
A Comprehensive Review of Organ-on-a-Chip Technology and Its Applications.器官芯片技术及其应用的全面综述
Biosensors (Basel). 2024 May 1;14(5):225. doi: 10.3390/bios14050225.
7
Allogeneic bone marrow mesenchymal stem cell-derived exosomes alleviate human hypoxic AKI-on-a-Chip within a tight treatment window.同种异体骨髓间充质干细胞来源的外泌体在严格的治疗窗口期内缓解人缺氧性 AKI-on-a-Chip。
Stem Cell Res Ther. 2024 Apr 10;15(1):105. doi: 10.1186/s13287-024-03674-8.
8
Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System.解决基于聚二甲基硅氧烷（PDMS）的芯片肠道微生理系统中化合物损失的吸收、分布、代谢和排泄（ADME）挑战。
Pharmaceutics. 2024 Feb 20;16(3):296. doi: 10.3390/pharmaceutics16030296.
9
Reproducibility and Robustness of a Liver Microphysiological System PhysioMimix LC12 under Varying Culture Conditions and Cell Type Combinations.肝脏微生理系统PhysioMimix LC12在不同培养条件和细胞类型组合下的可重复性和稳健性
Bioengineering (Basel). 2023 Oct 14;10(10):1195. doi: 10.3390/bioengineering10101195.
10
A new tissue-agnostic microfluidic device to model physiology and disease: the lattice platform.一种新型的组织非特异性微流控装置，用于模拟生理和疾病：晶格平台。
Lab Chip. 2023 Nov 7;23(22):4821-4833. doi: 10.1039/d3lc00378g.
本文引用的文献
1
Dental resins used in 3D printing technologies release ovo-toxic leachates.用于 3D 打印技术的牙科树脂会释放出卵毒性浸出物。
Chemosphere. 2021 May;270:129003. doi: 10.1016/j.chemosphere.2020.129003. Epub 2020 Dec 7.
2
Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies?现在是审稿人3要求进行人体器官芯片实验而非动物验证研究的时候了吗？
Adv Sci (Weinh). 2020 Oct 12;7(22):2002030. doi: 10.1002/advs.202002030. eCollection 2020 Nov.
3
Utilization of a model hepatotoxic compound, diglycolic acid, to evaluate liver Organ-Chip performance and in vitro to in vivo concordance.利用模型肝毒性化合物二甘醇酸评估肝器官芯片的性能和体外与体内的一致性。
Food Chem Toxicol. 2020 Dec;146:111850. doi: 10.1016/j.fct.2020.111850. Epub 2020 Nov 7.
4
Human in vitro vascularized micro-organ and micro-tumor models are reproducible organ-on-a-chip platforms for studies of anticancer drugs.人类体外血管化微器官和微肿瘤模型是可重现的类器官芯片平台，可用于研究抗癌药物。
Toxicology. 2020 Dec 1;445:152601. doi: 10.1016/j.tox.2020.152601. Epub 2020 Sep 24.
5
Integrated human organ-on-a-chip model for predictive studies of anti-tumor drug efficacy and cardiac safety.用于抗肿瘤药物疗效和心脏安全性预测研究的集成式人源器官芯片模型。
Lab Chip. 2020 Nov 24;20(23):4357-4372. doi: 10.1039/d0lc00424c.
6
Organs-on-chips: into the next decade.芯片器官：迈向新的十年。
Nat Rev Drug Discov. 2021 May;20(5):345-361. doi: 10.1038/s41573-020-0079-3. Epub 2020 Sep 10.
7
Advances in microphysiological blood-brain barrier (BBB) models towards drug delivery.微生理血脑屏障（BBB）模型在药物输送方面的进展。
Curr Opin Biotechnol. 2020 Dec;66:78-87. doi: 10.1016/j.copbio.2020.06.009. Epub 2020 Jul 22.
8
Human Organs-on-Chips for Virology.人源器官芯片在病毒学中的应用
Trends Microbiol. 2020 Nov;28(11):934-946. doi: 10.1016/j.tim.2020.06.005. Epub 2020 Jul 13.
9
Inotropic assessment in engineered 3D cardiac tissues using human induced pluripotent stem cell-derived cardiomyocytes in the Biowire II platform.在Biowire II平台上使用人诱导多能干细胞衍生的心肌细胞对工程化三维心脏组织进行变力性评估。
J Pharmacol Toxicol Methods. 2020 Sep;105:106886. doi: 10.1016/j.vascn.2020.106886. Epub 2020 Jul 3.
10
An Improved Vascularized, Dual-Channel Microphysiological System Facilitates Modeling of Proximal Tubular Solute Secretion.一种改进的血管化双通道微生理系统有助于近端肾小管溶质分泌的建模。
ACS Pharmacol Transl Sci. 2020 Jan 28;3(3):496-508. doi: 10.1021/acsptsci.9b00078. eCollection 2020 Jun 12.
Zotero 插件